Category:

Non-Life

47 districts reported over 10 pc COVID-19 positivity rate for week ending July 15: Govt

PM Modi said the country stands at a point in its battle with the pandemic where apprehensions about a third wave are being continuously expressed. These states have accounted for 80 percent of new COVID-19 cases last week and 84 percent of deaths, he noted in his closing remarks, specifically mentioning the rise in infections in Kerala and Maharashtra as a matter of grave concern for the country.

read more

DCGI examining Zydus Cadila’s COVID vaccine for children, says Dr VK Paul

The Centre in an affidavit told the Delhi High Court that pharmaceutical major Zydus Cadila’s COVID-19 vaccine may be available in the near future for children in the age group of 12 to 18 years. Zydus Cadila has concluded its trial for children between the age group of 12 to 18 and is subject to statutory permissions, the Centre added.

read more

No negligence of normal vaccination programme for children due to COVID-19 disruptions: Govt  

.“These reports are not based on facts and do not reflect the true picture and the Ministry along with all States and UTs and development partners, have worked towards mitigating negative impacts of COVID-19 and taking urgent actions to ensure that children receive life-saving vaccines under UIP,” said the ministry on Friday.

read more

Alcohol linked to over 62,000 cancer cases in India last year: Lancet study

These cancers have well-established causal links to alcohol consumption, and the estimates of the direct associations with alcohol in the new study are the first of their kind for 2020.”Trends suggest that although there is a decrease in alcohol consumption per person in many European countries, alcohol use is on the rise in Asian countries such as China and India, and in sub-Saharan Africa,” said Harriet Rumgay of the International Agency for Research on Cancer (IARC), France.

read more

Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

The litigation followed a public outcry in 2016 after Mylan, which owns the rights to market and distribute the devices, raised the price of a pair of EpiPens to $600, from $100 in 2008, putting it in the center of an ongoing U.S. debate over the high cost of medicines. The lawsuit accused Mylan and Pfizer, which manufactured the EpiPen for Mylan, of engaging in anticompetitive conduct that allowed them to maintain a monopoly over the market for the devices and their profitable revenues.

read more